高血压缓解了血β-粉样蛋白和认知障碍之间的关系:中国西安的一项横截面研究
Ziyu Liu1, Yaoli He2, Simeng Cui1
1Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Frontiers in aging neuroscience
|February 12, 2025
概括
高血压影响了血氨基酸β (Aβ) 和认知障碍 (CI) 之间的联系. 升高的Aβ水平表明高血压患者的CI风险,而降低的Aβ40表明没有高血压的人的CI风险.
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 老年学是一门学科.
背景情况:
- 血β-粉样蛋白 (Aβ) 水平是阿尔茨海默病和认知障碍 (CI) 的公认生物标志物.
- 关于血Aβ和CI之间的关联存在矛盾的发现.
- 高血压在这种关系中的缓解作用仍在调查中.
研究的目的:
- 调查高血压是否调节了血Aβ水平和认知障碍 (CI) 之间的关系.
- 探索血Aβ对高血压和无高血压个体的CI的影响差异.
主要方法:
- 一项涉及1488名40岁及以上中国西北农村40岁及以上受试者的横截面研究.
- 认知障碍 (CI) 被评估使用迷你精神状态检查.
- 分析了血Aβ40和Aβ42水平,并根据Aβ水平和高血压状态的组合对参与者进行了分类. 使用多变量逻辑回归.
主要成果:
- 同时增加的血Aβ40和Aβ42与高血压亚组的CI显著相关 (OR = 1.984,P = 0.030).
- 血Aβ40降低与非高血压小组的CI显著相关 (OR = 1.728,P = 0.043).
- 在对立的子组中没有观察到这些关联 (例如,非高血压中Aβ升高,高血压中Aβ40降低).
结论:
- 高血压显著调节了血Aβ生物标志物与认知障碍之间的关系.
- 同时升高的Aβ40/Aβ42和降低的Aβ40可能是CI的独特危险因素,取决于高血压状态.
- 这些发现强调了在使用血Aβ用于CI检测和风险评估时考虑高血压的重要性.
相关概念视频
Alzheimer's Disease: Overview
432
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
432
Alzheimer's Disease: Treatment
155
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
155


